UBS Group Issues Pessimistic Forecast for Zimmer Biomet (NYSE:ZBH) Stock Price

Zimmer Biomet (NYSE:ZBH) had its price objective dropped by analysts at UBS Group from $96.00 to $88.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “sell” rating on the medical equipment provider’s stock. UBS Group’s price objective points to a potential downside of 0.01% from the company’s current price.

ZBH has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, October 8th. Evercore ISI reduced their target price on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a report on Tuesday, October 7th. Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Raymond James Financial boosted their price target on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Finally, Roth Capital restated a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $109.42.

Zimmer Biomet Trading Up 0.5%

Shares of ZBH stock traded up $0.46 during trading hours on Thursday, reaching $88.01. The company had a trading volume of 2,197,702 shares, compared to its average volume of 1,922,379. The firm has a market cap of $17.43 billion, a price-to-earnings ratio of 21.36, a P/E/G ratio of 2.29 and a beta of 0.67. Zimmer Biomet has a 1-year low of $85.33 and a 1-year high of $114.72. The company has a 50 day moving average of $100.84 and a 200 day moving average of $97.60. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same period in the previous year, the company posted $1.74 earnings per share. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts anticipate that Zimmer Biomet will post 8.22 EPS for the current year.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the sale, the senior vice president directly owned 6,833 shares in the company, valued at $711,656.95. The trade was a 18.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 1.39% of the company’s stock.

Institutional Investors Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently modified their holdings of ZBH. Ameriprise Financial Inc. grew its stake in shares of Zimmer Biomet by 236.0% in the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock valued at $517,039,000 after acquiring an additional 3,208,596 shares in the last quarter. Dodge & Cox boosted its holdings in Zimmer Biomet by 12.9% in the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock valued at $2,015,510,000 after purchasing an additional 2,533,009 shares during the period. Norges Bank acquired a new position in shares of Zimmer Biomet during the 2nd quarter worth approximately $225,867,000. JPMorgan Chase & Co. increased its holdings in shares of Zimmer Biomet by 251.3% during the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after purchasing an additional 1,488,918 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Zimmer Biomet in the first quarter valued at approximately $155,891,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.